Table 2.

Hormone concentrations in case-control pairs

Hormone	Cases (n = 153)		Controls (n = 153)	Paired t test (P)	HR (95% CI)	P
	Mean (SD)	Median (interquartile range)	Mean (SD) pairwise difference
Estradiol (pg/mL)	22.7 (56.0)	8.2 (5.8−13.3)	−11.8 (51.2)	0.05	1.41 (1.01−1.97)	0.04
Bioavailable estradiol (pg/mL)	12.5 (29.8)	4.64 (2.8−9.1)	−6.4 (26.8)	0.02	1.26 (1.03−1.53)	0.02
Free estradiol (pg/mL)	0.47 (1.12)	0.17 (0.11−0.34)	−0.24 (1.01)	0.02	1.31 (1.03−1.65)	0.03
Testosterone (ng/dL)	30.6 (18.7)	25.8 (19.5−36.7)	−1.8 (24.4)	0.99	1.15 (0.75−1.74)	0.52
Bioavailable testosterone (ng/dL)	12.4 (8.8)	10.7 (7.5−13.7)	−1.7 (10.6)	0.52	1.21 (0.82−1.80)	0.33
Free testosterone (pg/mL)	4.8 (3.4)	4.2 (2.9−5.3)	−0.7 (4.1)	0.53	1.21 (0.82−1.80)	0.33
SHBG (nmol/L)	75.0 (40.7)	68.0 (46.5−93.5)	+5.6 (58.7)	0.24	0.86 (0.56−1.33)	0.51

NOTE: Values shown are mean (SD) and median (interquartile range) for recurred women (cases), median (SD) difference in controls, significance level for paired t tests, HR (95% CI), and significance level for a Cox model of time to event adjusted for tumor grade (153 pairs) in the nested case-control cohort of the WHEL Study.

Paired t tests and Cox models were conducted using log-transformed pairwise data. HRs reflect risk per unit increase in log of hormone concentration.